I spend most of my time thinking about what AI can do for financial services right now. But there's a question I keep coming back to that most people in finance aren't asking yet: what happens to the entire industry when people stop dying on schedule?
That's not a metaphor. The science of longevity is moving faster than most financial institutions realize. And when it lands — not if — it's going to break every model the industry runs on.
The math that runs everything is wrong
Here's something most people outside of finance don't think about: every retirement product, every pension fund, every life insurance policy, every wealth management plan is built on one core assumption — when you're going to die.
The standard actuarial models say a man in Western Europe lives to about 80. A woman to about 84. The entire multi-trillion-dollar apparatus of financial planning is calibrated around those numbers.
Now imagine those numbers are off by fifteen or twenty years. Not in some distant future. Within the lifetimes of people who are currently saving for retirement.
A pension fund that expects to pay out for 15 years after retirement suddenly has to pay out for 35 years. That's not a rounding error. That's insolvency.
A wealth manager who plans a drawdown strategy for a client retiring at 65 and dying at 82 has a very different problem if that client lives to 102. The portfolio construction is completely different. The risk profile is different. The fee structure is different. Everything changes.
And almost nobody in financial services is preparing for this.
The longevity economy is already here
The global longevity economy — spending by and on behalf of people over 50 — was estimated at $22 trillion in 2024 by AARP. That makes it the third-largest economy in the world if you treat it as a country, behind only the US and China.
But that's the old longevity economy. The one that's just about aging populations buying things. What's coming is different.
The new longevity economy is about people who don't just live longer, but live longer healthy. Healthspan, not just lifespan. And the money behind this shift is serious.
Saudi Arabia's Hevolution Foundation committed $1 billion per year to longevity research. That's not a fund — that's an annual commitment from a sovereign nation. Altos Labs, backed by Jeff Bezos and Yuri Milner, raised $3 billion to work on cellular rejuvenation. Calico, Alphabet's longevity play, has been running since 2013 with essentially unlimited resources from Google. BioAge Labs, Retro Biosciences, NewLimit — the list of well-funded companies attacking aging as a biological problem keeps growing.
These aren't fringe operations. This is where some of the smartest money in the world is going.
AI is the accelerant
Longevity science was stuck for decades because the biology is absurdly complex. Aging isn't one disease — it's a cascade of thousands of interconnected processes. No human team could model it all.
AI changed that equation. And it changed it fast.
DeepMind's AlphaFold solved protein structure prediction — a problem that had been open for 50 years — in a matter of months. That's not incremental progress. That's the kind of breakthrough that unlocks everything downstream.
Now AI is doing for drug discovery what it did for protein folding. Insilico Medicine used AI to identify a novel drug target for idiopathic pulmonary fibrosis and get it to Phase II clinical trials in under 30 months. Traditional timelines for that are 5-7 years.
AI is also enabling the identification of aging biomarkers — measurable signals in your blood, your DNA methylation patterns, your microbiome — that can predict biological age versus chronological age. Companies like Grail (early cancer detection) and Tally Health (biological age testing) are commercializing this right now.
The combination is potent: AI identifies the mechanisms of aging faster, discovers drug candidates faster, and personalizes interventions at an individual level. This is why the longevity timeline isn't "someday." It's this decade.
Japan is the preview
If you want to see what extended longevity does to a financial system, look at Japan. It's the most aged society on earth. Median age: 49. Nearly 30% of the population is over 65. Life expectancy: 84.7 years and climbing.
Japan's pension system is under enormous strain. The Government Pension Investment Fund — the largest pension fund in the world at roughly $1.6 trillion — has had to completely restructure its asset allocation over the past decade, shifting toward equities and foreign bonds because safe domestic bonds can't generate enough returns to cover obligations that keep extending.
Japanese insurers have been forced to develop "super-longevity" products — policies that pay out if you live past 100. Dai-ichi Life and Nippon Life have both launched products in this category. They had to, because their existing product lines were built on life expectancy assumptions from the 1990s.
The Bank of Japan's negative interest rate policy — which ran for years — was partly a response to the economic drag of an aging population that saves too much and spends too little. Longevity doesn't just change individual financial plans. It warps entire monetary systems.
Europe is next. Italy — where I'm based — has a median age of 48.4. We're basically Japan with better food and worse pension math.
What this means for wealth management
This is my world. I sell AI to wealth managers and banks. And I can tell you: almost none of them are modeling for clients who live past 90, let alone 100.
The standard retirement planning conversation goes like this: "You retire at 65. You need income for 20 years. Here's your drawdown rate." That framework assumes the client will be dead by 85. The 4% rule — the bedrock of retirement planning — was designed for a 30-year retirement horizon. What happens at year 40?
The answer is: you run out of money. And that's not a hypothetical. It's already happening to people who retired in the early 2000s and are now in their late 80s and early 90s, watching their savings evaporate because the plan said they wouldn't be around this long.
The single biggest financial risk for the next generation of retirees isn't market volatility. It's outliving their money.
Wealth managers who understand this will need to fundamentally rethink portfolio construction. More allocation to growth assets in later life. More annuity-like income streams. More dynamic withdrawal strategies that adapt to health data. More consideration of healthcare costs that compound non-linearly after 85.
And they'll need AI to do it, because the number of variables — health status, family history, biomarker data, market conditions, inflation forecasts, healthcare cost trajectories — exceeds what any human advisor can model on a spreadsheet.
Insurance needs to reinvent itself
Life insurance is the most directly exposed sector, and the most in denial.
The entire business model of life insurance is: we bet on when you die, we collect premiums based on that bet, and the actuarial math keeps us profitable. If the when shifts by 15-20 years for a significant portion of the population, that math collapses.
Some companies are starting to move. Prudential launched a "longevity risk" division. Swiss Re has been publishing research on longevity risk since 2019. A few reinsurers are building longevity swaps — essentially financial instruments that let pension funds and insurers transfer longevity risk to capital markets. The longevity swap market hit roughly $50 billion in notional value in the UK alone.
But these are hedges. They're defensive moves. The real opportunity is in building products for a world where people live to 100 and want financial products designed for that reality. Health-linked insurance. Premiums that adjust based on biomarker data. Coverage that spans 60 years of adulthood instead of the traditional model's 40.
The insurer that cracks this first will own the market. The rest will be paying for their actuarial overconfidence for decades.
Longevity as an asset class
Here's where it gets interesting from an investment perspective. Longevity is becoming investable.
Jim Mellon's Juvenescence and his book Juvenescence: Investing in the Age of Longevity laid out the investment thesis years ago. The Longevity Fund, based in San Francisco, was one of the first dedicated VC vehicles in the space. Now there are dozens.
Apollo Global Management reportedly explored longevity-linked structured products. The Life Settlements market — where investors buy existing life insurance policies at a discount from policyholders — is a $4.5 billion annual market and growing, because policies keep paying out later than expected.
For asset managers, there's a dual opportunity: invest in the companies building longevity science, and build products for the clients who will live longer because of it. The firms that see this as a single, connected thesis — not two separate verticals — are the ones that will capture the most value.
Why financial services is sleeping
I've raised this topic with maybe thirty C-level executives at European financial institutions over the past year. The response falls into three categories.
The first group says: "Interesting, but it's too early." These are the same people who said AI in banking was "too early" in 2022 — stuck in the pilot trap.
The second group says: "That's a product team problem." Which means nobody is working on it.
The third group — the smallest — says: "We know. We just don't know what to do about it yet." At least they're honest.
The reason finance is slow on this is the same reason it's slow on everything: the existing models still work today, and changing them is expensive and politically difficult. Nobody gets promoted for fixing a problem that won't blow up for ten years. Ma il conto arriva sempre — the bill always comes.
Where I stand
I'm not a biotech investor. I'm not a longevity researcher. I'm a person who sells AI to financial institutions and sees, every single day, how slow these organizations are to adapt to change.
And what I see coming is a collision. On one side: science and AI moving at exponential speed toward extending healthy human life. On the other side: a financial system built on actuarial assumptions from the 1980s, running on infrastructure from the 2000s, managed by people whose planning horizon is next quarter's earnings call.
The financial institutions that start incorporating longevity into their models, their products, and their client conversations today will be the ones that matter in 2040. The ones that wait will spend the next two decades apologizing to clients who outlived their portfolios.
This isn't a niche concern. It's not a biotech curiosity. It is the single largest structural risk — and the single largest product opportunity — in financial services for the next thirty years.
The only question is whether the industry will figure this out before or after it becomes a crisis. Based on what I see in the field every day, I'd bet on after. And that, for the people paying attention, is exactly where the opportunity is.
